Pasireotide, a somatostatin analog peptide, normalizes cortisol in up to 28% of Cushing's disease patients as monotherapy and up to 50% when combined with cabergoline.
28% cortisol normalization (monotherapy)As the first FDA-approved medical therapy for Cushing's disease, pasireotide normalizes cortisol in about 1 in 4 patients alone, increasing to 50% with cabergoline and higher with triple therapy.
What the researchers found
Pasireotide, a multi-receptor somatostatin analog peptide with high affinity for SST receptor 5, normalized urinary free cortisol levels in up to 28% of patients with Cushing's disease at doses of 600-1,200 μg twice daily after 3 months. Combining pasireotide with cabergoline increased the normalization rate to 50%, and adding ketoconazole achieved biochemical control in most patients. Treatment improved blood pressure, weight, lipid profile, and quality of life. Hyperglycemia is the main side effect, caused by pasireotide's suppression of insulin and GLP-1 secretion.
Why it matters
Cushing's disease is a serious condition caused by excess cortisol from a pituitary tumor. Before pasireotide, there was no FDA-approved medical therapy specifically targeting the pituitary tumor cells. Pasireotide represents a milestone as the first peptide drug approved for this indication, working by targeting SST receptor 5 — the predominant somatostatin receptor in corticotroph tumors that remains functional even when cortisol levels are high.
The numbers in context
600-1,200 μg twice daily · 28% cortisol normalization as monotherapy · 50% normalization with cabergoline combo · most patients controlled with triple therapy · FDA and EMA approved
How the study worked
This is a clinical review summarizing the pharmacology, clinical trial results, efficacy data, adverse effects, and practical management considerations for pasireotide use in adult Cushing's disease. It covers both monotherapy and combination therapy approaches.
Who was studied
Adults with Cushing's disease (recurrent after surgery or not surgical candidates)
What this study cannot tell us
As a review, no new data are presented. The normalization rate of 28% as monotherapy means most patients don't achieve full biochemical control with pasireotide alone. Hyperglycemia is a significant and common side effect that complicates management. Long-term efficacy and safety data beyond the initial clinical trials were limited at the time of publication.
How to read the evidence
This review summarizes data from phase II and III clinical trials that led to FDA and EMA approval of pasireotide for Cushing's disease. The regulatory approval indicates a high level of clinical evidence, though the review itself is a narrative synthesis.
When this study was published
Published in 2015, shortly after pasireotide's regulatory approval. Since then, a long-acting monthly formulation (pasireotide LAR) has been developed, and more clinical experience has accumulated.
The bigger picture
Pasireotide exemplifies how understanding receptor pharmacology can lead to targeted peptide therapeutics. While older somatostatin analogs like octreotide targeted SST receptor 2 (which is downregulated by high cortisol), pasireotide was designed to target SST receptor 5, which remains active. This receptor-specific approach represents a broader trend in peptide drug design — creating analogs with tailored receptor binding profiles for specific disease applications.
Questions still open
- Can newer formulations of pasireotide (long-acting monthly injections) improve patient compliance and outcomes?
- Could combining pasireotide with GLP-1 receptor agonists address both the cortisol excess and the hyperglycemia side effect simultaneously?
- What are the long-term outcomes of pasireotide therapy beyond the initial clinical trial follow-up periods?
Common questions
How does pasireotide differ from older somatostatin analogs like octreotide?
Why does pasireotide cause high blood sugar?
Read the original research
Clinical use of pasireotide for Cushing's disease in adults.
Therapeutics and clinical risk management, 11, 425-34
Citation
Ceccato, Filippo; Scaroni, Carla; Boscaro, Marco. (2015). Clinical use of pasireotide for Cushing's disease in adults.. Therapeutics and clinical risk management, 11, 425-34. https://doi.org/10.2147/TCRM.S37314